YouTube Facebook LinkedIn Google+ Twitter Xingrss  

UC Santa Cruz Wins DREAM Breast Cancer Challenge


By Bio-IT World Staff  
 
November 8, 2013 | A team of bioinformatics experts at UC Santa Cruz made the most accurate predictions in a competitive challenge to identify signaling networks in breast cancer cells. The results of the HPN-DREAM breast cancer network inference challenge were announced today in Toronto.  
 
The breast cancer network inference challenge was organized by the DREAM project (Dialogue on Reverse Engineering Assessment and Methods), which has coordinated 27 DREAM challenges over the past seven years (see, “DREAM Project Vision Expands”). 
 
The goal of the challenge was to uncover some of the important protein signaling networks in breast cancer cells. The organizers, in collaboration with several cancer research labs, carried out a series of experiments on breast cancer cells grown in the laboratory, subjecting them to various stimuli and inhibitors and measuring the activity of about 45 proteins of interest over a period of four hours. Participants were given data from these experiments and challenged to predict causal links between proteins, such as "activity of protein A promotes (or inhibits) activity of protein B."
 
"Our goal is to understand the underlying biology of cancer cells and, specifically, how genes interact with each other. The DREAM Challenge was an opportunity to test our expertise in a competitive environment," said Artem Sokolov in a statement. Sokolov is a postdoctoral scholar who works with Josh Stuart, professor of biomolecular engineering in UCSC's Baskin School of Engineering, and led the team of researchers in Stuart's lab who worked on the challenge.
 
"Protein-protein interactions are at the heart of many biological processes in a cell," Sokolov explained. Cell proteins form signaling networks, better known as pathways, which can pass messages from chemical receptors on the cell surface to other parts of the cell. Many cancer therapies attempt to identify overactive pathways and shut them down using inhibitors. "Unfortunately, our understanding of the underlying signaling circuitry is still limited, making the task difficult," Sokolov said.
 
The UCSC team combined two approaches, borrowing algorithms from unrelated fields. The "biological prior" component used heat-diffusion equations from physics to analyze information already available in a database of protein interactions. Another component of their method, developed by graduate student Dan Carlin, used an idea from economics called "Granger Causality" to find correlations. In addition to Sokolov and Carlin, the team includes graduate students Evan Paull, Kiley Graim, and Adrian Bivol, undergraduate Alden Deran, and staff researcher Chris Wong. They have been invited to submit a paper describing their methods for publication in Nature Methods. 
 
In addition to advancing the basic understanding of the biology of cancer cells, this research could have practical applications, Sokolov said. Drug companies, for example, might use a computational analysis of signaling networks to predict how a potential drug compound would affect cancer cells, helping them select the most promising leads for further investigation. 
 
Dream On 
 
The next DREAM Challenge—Somatic Mutation Calling—will merge the efforts of the world's largest cancer genome sequencing consortia--the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA)--with those of Sage Bionetworks and the DREAM project (see, “DREAM Project and Sage Bionetworks Join Forces”). Data will be hosted on a petabyte-capacity data storage system provided to UCSC by Hitachi.
 
The specific problem the somatic mutation calling challenge will address is the need for accurate methods to identify cancer-associated mutations from whole-genome sequencing data. Although today's DNA sequencing instruments can amass great quantities of sequence data from a patient's normal and tumor tissues, the ability to identify DNA mutations and rearrangements accurately on the basis of those data remains elusive; current studies agree in only about 20% of their predictions.
 
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact  Jay Mulhern, (781) 972-1359, jmulhern@healthtech.com.